Core Viewpoint - Investing in Pfizer, despite its declining share price, may present a significant opportunity due to its ongoing growth strategies and attractive valuation metrics [1][7]. Financial Performance - Pfizer's year-end numbers for 2024 showed a 7% increase in total sales, despite a 52% decline in COVID vaccine sales to $5.4 billion [3]. - The specialty care segment grew by 11%, and the oncology business expanded by 25% following the acquisition of Seagen [3]. - The primary care business experienced only a 2% decline year-over-year, indicating resilience despite the drop in COVID-related revenue [3]. Market Sentiment and Valuation - Pfizer's stock has lost half its value over the past three years, leading to a perception of it being a high-risk investment primarily associated with COVID [5]. - The stock is currently trading at 18 times trailing earnings and less than 9 times forward price-to-earnings, significantly lower than the average in the Health Care Select Sector SPDR Fund, which trades at over 18 times future profits [8]. Long-term Outlook - Concerns about losing patent protection on key drugs like Eliquis and Vyndaqel are common in the pharmaceutical industry, but Pfizer's focus on acquisitions and pipeline investments positions it well for future growth [4][10]. - The potential appointment of Robert F. Kennedy Jr. to a government position has raised investor apprehension, but such political changes may not have a lasting impact on Pfizer's long-term business trajectory [6][10]. Investment Consideration - The current negative sentiment surrounding Pfizer may create a buying opportunity for investors, as the stock's performance does not reflect the underlying business health [9]. - Pfizer offers a high-yield dividend of 6.6%, providing an incentive for long-term investors to remain patient despite short-term volatility [11].

Providing alpha-generating investment ideas. I am an independent investor managing my family's portfolio, primarily via a Self Managed Super Fund. You can expect my articles to deliver a clearly structured, evidence-based thesis. But first and foremost, I encourage readers to judge me on my performance.I have a generalist approach as I explore, analyze and invest in any sector so long there is perceived alpha potential vs the S&P500. The typical holding period ranges between a few quarters to multiple years ...

Pfizer’s (PFE)  fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago quarter. Revenues came in at $17.76 billion, up 22% from the year-ago quarter.Higher sales of Pfizer’s key non-COVID products like Vyndaqel, Padcev and Eliquis and newly acquired products from Seagen, coupled with higher Paxlovid sales, drove the top line in the quarter. However, sales of some key drugs like Prevnar, Xel ...

Pfizer Inc. 's (NYSE: PFE ) stock price continued stagnating over the last three months, which reinforces my cautious stance I discussed in November . Despite being one of a few companies that helped to save theComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies paid off and now I feel very confident i ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.Which of these two high-yield dividend payers is best for your portfolio? Let's weigh their strong points against some of the challenges they face, to see which stock is a better buy now.The case for MerckShares of Merck have fallen ...

The past three years have been difficult for Pfizer (PFE -0.35%). The pharmaceutical giant's financial results worsened substantially as its coronavirus-related tailwind came to a screeching halt. Investors responded by sending the stock down significantly. Pfizer has lost about 50% of its market value in the past three years. If the stock can bounce back and deliver excellent returns over the long run, initiating a position today might be a great idea. Are there good reasons to think Pfizer has what it tak ...

CHINA - 2024/09/21: In this photo illustration, a Pfizer logo is displayed on the screen of a ... [+] smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesPfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per share, compared to the consensus estimates of $17.4 billion and $0.46, respectiv ...

Pfizer (PFE) reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.Find the latest EPS estimates and surprises on Zacks Earnings Calendar. Revenues came in at $17.76 billion, up 22% from the year-ago quarter on a reported basis. Revenues reflected an operational increase of 21% and a positive currency impact of 1%. Total revenues also beat the Zacks C ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Pfizer (PFE) reported $17.76 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 24.7%. EPS of $0.63 for the same period compares to $0.10 a year ago.The reported revenue represents a surprise of +1.52% over the Zacks Consensus Estimate of $17.5 billion. With the consensus EPS estimate being $0.48, the EPS surprise was +31.25%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...